Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Inventory (2021 - 2025)

Historic Inventory for Ascendis Pharma A (ASND) over the last 5 years, with Q4 2025 value amounting to $351.0 million.

  • Ascendis Pharma A's Inventory rose 1112.52% to $351.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $351.0 million, marking a year-over-year increase of 1112.52%. This contributed to the annual value of $340.8 million for FY2025, which is 787.52% up from last year.
  • Per Ascendis Pharma A's latest filing, its Inventory stood at $351.0 million for Q4 2025, which was up 1112.52% from $315.9 million recorded in Q4 2024.
  • Ascendis Pharma A's 5-year Inventory high stood at $351.0 million for Q4 2025, and its period low was $86.3 million during Q4 2021.
  • Its 5-year average for Inventory is $222.3 million, with a median of $224.8 million in 2023.
  • As far as peak fluctuations go, Ascendis Pharma A's Inventory skyrocketed by 6861.63% in 2023, and later skyrocketed by 1112.52% in 2025.
  • Over the past 5 years, Ascendis Pharma A's Inventory (Quarter) stood at $86.3 million in 2021, then skyrocketed by 54.55% to $133.3 million in 2022, then skyrocketed by 68.62% to $224.8 million in 2023, then soared by 40.52% to $315.9 million in 2024, then rose by 11.13% to $351.0 million in 2025.
  • Its Inventory was $351.0 million in Q4 2025, compared to $315.9 million in Q4 2024 and $224.8 million in Q4 2023.